Asthma and COPD are the most common respiratory diseases
Chiesi is working to develop and manufacture medicinal products for people with respiratory diseases, including asthma and COPD (chronic obstructive pulmonary disease), and to improve their quality of...
Normally, giving birth takes place between the 37th and 42nd week of pregnancy. The foetus has fully come to term by then and is sufficiently developed to be able to adapt to life outside the womb. Sometimes,...
The term rare applies to those diseases that affect a limited number of people, and have a prevalence lower than a legislatively determined threshold in each country. In the EU, this threshold is set at 0.05% of the...
Kidney and liver failure: Organ transplantation
Organ failure means that an organ loses the ability to perform its physiological functions, and this creates a potential threat to the patient's quality of life and survival.
The kidneys have a number of physiological functions,...
We are an international company, with our headquarter based in Parma, Italy. With 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative...
-
Chiesi develops and distributes pharmaceuticals in 65 countries and has 25 international companies (in Europe, America, Asia and Africa). Today, Chiesi is one of the world's leading pharmaceutical companies in the...
Here you can find declarations of value transfers from Chiesi to health care professionals (HCP) and health care organisations (HCO).
Innovation is the driving force behind every technologically advanced industry, but for the pharmaceutical industry it plays a vital role since it concerns the health and quality of life of people....
We have a strong pipeline for respiratory diseases, neonatology, special care and rare diseases. Please find more information at Chiesi.com research and development
Thanks to four international research facilities, we can maintain a high level in the development and manufacture of innovative new drugs. Our plants are located in Paris (France), Rockville (USA), Chippenham...
-
Chiesi is one of Europe's leading pharmaceutical companies. The company was founded in Italy in 1935 and today offers drugs in over 65 countries. We have been in the Nordic region since 2013.
Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to patient safety and the risk-benefit ratio of our...
You are always welcome to contact us by telephone or email if you have questions or wish to know more about any medicine.
However, in accordance with Swedish law, we cannot give out any information about our medicines to patients.
The following must be used for submitting...
-
What are cookies?
Cookies are small information files that – when you connect to a Web site – are transferred to your computer and stored in association with the files used by the browser.
Why use cookies?
Chiesi Pharma AB...
This homepage was edited and produced by Dynamic Mind.
You are always welcome to contact us by telephone or email if you have questions or wish to know more about any medicine.
Local Press Officer:
Olav Fromm, Managing...
Lämpimästi tervetuloa Chiesin järjestämälle lounasluennolle torstaina 26.10.2017.
Luennoitsijana toimii dosentti, osastonlääkäri Witold Mazur, HUS Sydän ja keuhkokeskus, Meilahden sairaalasta. Luennon aihe on COPD:n nykyaikainen...
-
We Act - We Actively Care for Tomorrow, is an expression of Chiesi's desire to promote sustainable conduct. We Act is a group-wide programme with initiatives for co-workers regarding the environment and the local community, for the benefit of both Chiesi and those affected by Chiesi. (Read our...
Sustainability is central to Chiesi, a family-owned pharmaceutical group based in Parma, Italy. Chiesi Group’s claim is “Let’s make the world feel better”. As a Benefit Corporation, it is committed to acting as a force for good,...
Chiesi wants to contribute to economic, social, environmental and cultural sustainability in society. In order to ensure a positive impact on society, a dialogue is conducted with local stakeholders to develop social and cultural projects in joint networks.
We are committed to taking care of our patients while keeping a keen eye on the environment and reducing our carbon footprint. We take climate change seriously and take specific action in this respect. To this end, we have set ourselves a challenging goal: To become Carbon Neutral by...
1. Scope of the privacy policy
1.1 Below is a description of how Chiesi Pharma AB, company registration number 556827-5746, with the address Klara Norra Kyrkogata 34, 111 22, Stockholm, (“Chiesi”, “us” or...
An opportunity for a career in a global setting
For those interested in, or with previous experience from the pharmaceutical industry, Chiesi offers the opportunity for further career development, enabling you to enhance your competences by working directly on complex projects requiring...
A pharmaceutical company with sustainability in focus
We are passionate about improving and raising people’s quality of life.
Chiesi is a B-Corp certified company, which means that we want our profits to come from creating increased value for everyone,...
Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our planet
Chiesi is one of Europe's leading pharmaceutical companies. The company was founded in Italy in 1935 and today offers drugs in over 65 countries. We have been in the Nordic region since 2013.
-
Here we gather information regarding education and seminars, you can also order material and book digital or personal meetings with our local representatives. Our ambition is to help you do a good job even better.
-
-
Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science and has always been at the...
In Chiesi Pharma 2024 sustainability report you find our actions from the Nordic organisation and in the corporate sustainability report you find the actions from the global organisation.
The Nordic sustainability report focuses on Chiesi's sustainability footprint and...
-
PRIVACY NOTICE
This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing...
-
Everyone of us is different, everyone of us is Chiesi.
Chiesi Nordic is committed to put our people at the centre. We strive to hire a diverse work force at all levels of our business, as it is our belief that a mix of different backgrounds and personalities form...
Our partnerships
For us at Chiesi Pharma, partnerships are important. We look for relationships characterized by mutual understanding of the sustainability challenges we face. We also think it is important to be able to disclose the relationships we...
-
-
-
-
-
EPIDERMOLYSIS BULLOSA (EB)
Epidermolysis Bullosa (EB) on perinnöllinen, harvinainen ja vakava ihosairaus. Sairaus aiheuttaa ihon haurautta ja rakkuloita. Vakavissa tapauksissa useat elimet kärsivät arpeutumisesta ja lyhentyneestä...
LIPODYSTROFIA
Lipodystrofia (LD) -oireyhtymät ovat kokoelma harvinaisia, heterogeenisiä sairauksia, jotka johtuvat viallisesta rasva-aineenvaihdunnasta, jolle on tunnusomaista rasvakudoksen atrofia.1 Tämä sisältää yleisen,...
HOMOTSYGOOTTINEN FAMILIAALINEN HYPERKOLESTEROLEMIA (HOFH)
Homotsygoottinen familiaalinen hyperkolesterolemia (HoFH) on harvinainen perinnöllinen sairaus, joka vaikuttaa sekä miehiin että naisiin. HoFH on hengenvaarallinen sairaus, jolle on tunnusomaista niin...
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy.
The results of the study provide convincing support...Chiesi receives today the Certificate Top Employers Europe for the fourth year in a row. The prize is assigned only to those organisations that create optimal employee conditions, upon evaluation of the HR strategies and policies. The CRF Institute uses a proprietary method based on the HR...
Alberto, Paolo and Andrea Chiesi are the National winners of the EY “ L’Imprenditore dell’Anno 2015” Award. The prestigious recognition, promoted by EY-Ernst & Young and sponsored by Azimut Wealth Management, is now at its 19th edition. The...
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients Chiesi Global Rare Diseases unit...Market leader in respiratory innovation highlights potentially harmful[1] consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI)...
The Group commits €3 million for donations to support the ongoing emergency Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world Company also announces a €1 million investment in new...
-
Mechanisms and physiology of asthma
Presented by Prof. Arnaud Bourdin
The asthma session started off with Prof. Arnaud Bourdin talking about mechanisms and physiology of asthma. Prof. Bourdin provided...
Real world use of cangrelor in patients undergoing Percutaneous
Coronary Interventions (PCI)
Friday, April 28th, 2023 at 10.30 – 11.15
PIENI SALI, TAMPERE-TALO
Download PDF
Stockholm, October 16, 2023 - Chiesi, the international research-focused biopharmaceutical group, and the prestigious Karolinska Institutet (KI) have joined forces in a new collaborative research agreement. This partnership is focused on advancing the biological characterization of patients...
